0.2343
Vor Biopharma Inc (VOR) 最新ニュース
Vor Biopharma Inc (NASDAQ: VOR) Stock Forecast: Could Pass $6 In A Year - Stocksregister
Vor Biopharma’s SWOT analysis: biotech firm halts programs, explores options - Investing.com
Vor Biopharma Approves Share Increase at Annual Meeting - TipRanks
Vor Biopharma Appoints Robert Ang as CFO - TipRanks
What Did We Note About Insider Trading At Vor Biopharma Inc (NASDAQ: VOR)? - Stocksregister
FMR LLC's Strategic Acquisition of Vor Biopharma Inc Shares - GuruFocus
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of “Hold” by Analysts - Defense World
Vor Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Vor Biopharma Inc. SEC 10-Q Report - TradingView
Research Analysts’ Recent Ratings Updates for Vor Biopharma (VOR) - Defense World
Vor Biopharma (NYSE:VOR) Cut to “Hold” at Jones Trading - Defense World
JMP Securities Reiterates “Market Perform” Rating for Vor Biopharma (NYSE:VOR) - Defense World
Vor Biopharma’s (VOR) Neutral Rating Reiterated at Wedbush - Defense World
Vor Biopharma (VOR) Downgraded by HC Wainwright & Co. from Buy t - GuruFocus
VorBio (VOR) Downgraded Amid Strategic Review Announcement | VOR Stock News - GuruFocus
Vor Biopharma (VOR) Drops Sharply After Downgrades and Operational Halt - GuruFocus
Stifel cuts Vor Biopharma stock rating amid clinical and financial concerns By Investing.com - Investing.com South Africa
VorBio (VOR) Downgraded as Company Explores Strategic Alternativ - GuruFocus
Stifel cuts Vor Biopharma stock rating amid clinical and financial concerns - Investing.com Canada
Vor Biopharma stock draws downgrades (VOR:NASDAQ) - Seeking Alpha
Layoff Tracker: Shape, Vor Cut Workforces - BioSpace
Vor Biopharma (VOR) Downgraded by JMP Securities | VOR Stock New - GuruFocus
Baird Downgrades Vor Biopharma to Neutral From Outperform - marketscreener.com
This International Paper Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday - Benzinga
Vor Biopharma (VOR) Downgraded by HC Wainwright & Co. from Buy to Neutral | VOR Stock News - GuruFocus
Closing Bell Recap: Vor Biopharma Inc (VOR) Ends at 0.16, Reflecting a -70.12 Downturn - DWinneX
VorBio (VOR) Downgraded as Company Shifts Strategy | VOR Stock News - GuruFocus
VorBio (VOR) Downgraded as Company Explores Strategic Alternatives | VOR Stock News - GuruFocus
Stifel Downgrades Vor Biopharma, Inc. (VOR) to Hold - StreetInsider
Baird cuts Vor Biopharma stock rating, slashes target to $0.25 By Investing.com - Investing.com Nigeria
Baird cuts Vor Biopharma stock rating, slashes target to $0.25 - Investing.com
Jones Trading cuts Vor Biopharma stock rating to Hold By Investing.com - Investing.com Nigeria
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings - Benzinga
Jones Trading cuts Vor Biopharma stock rating to Hold - Investing.com
Vor Biopharma stock plummets on operation wind-down - Investing.com Australia
Vor Biopharma stock plummets on operation wind-down By Investing.com - Investing.com Canada
Vor Biopharma Terminates CFO Han Choi - marketscreener.com
Vor Bio Announces Exploration Of Strategic Alternatives To Maximize Shareholder Value - marketscreener.com
Wedbush Downgrades Vor Biopharma to Neutral From Outperform, Adjusts Price Target to $0.40 From $7 - marketscreener.com
Vor Bio (VOR) Downgraded to Hold as Strategic Alternatives Explored | VOR Stock News - GuruFocus
Jones Trading Downgrades Vor Biopharma, Inc. (VOR) to Hold - StreetInsider
Dow Jumps Over 200 Points; US Initial Jobless Claims Fall - Benzinga
Vor Bio (VOR) Explores Strategic Alternatives Amid Operational Wind Down | VOR Stock News - GuruFocus
Vor Biopharma (VOR) Announces Exploration of Strategic Alternatives, Winding Down Operations - StreetInsider
Marshall Wace LLP Sells 79,445 Shares of Vor Biopharma Inc. (NYSE:VOR) - Defense World
Vor Biopharma Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
XTX Topco Ltd Acquires New Position in Vor Biopharma Inc. (NYSE:VOR) - The AM Reporter
Crescent Biopharma Appoints David Lubner to Board of Directors - The Manila Times
PureTech Founded Entity Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined with a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML) - The Globe and Mail
Vor Biopharma faces Nasdaq delisting over low stock price - Investing.com
Vor Biopharma faces Nasdaq delisting over low stock price By Investing.com - Investing.com India
大文字化:
|
ボリューム (24 時間):